The latest pharmaceutical and medical device news of importance to you and your practice.
Seizure Drug Labels Warn of New Dangers
In a letter sent April 18, Novartis Pharmaceuticals and the Food and Drug Administration (FDA) notified health care professionals about revisions to the “Warnings” and “Precautions” sections of the prescribing information for Trileptal'(oxcarbazepine) tablets and oral suspension.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
NOT FOR REPRINT
© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.
As quantum machines become more powerful, today’s uncrackable encryption schemes may become trivial to break. Opinions vary as to how soon that moment, so-called “Q Day,” will arrive, but the threat is real.
How do you communicate when you know the harm before you know its cause? For law firms, it comes up both when advising a client and when explaining an incident of their own.
The gap between what a firm bills and what it collects is not a collections failure. It is a design flaw in how the whole revenue cycle is wired, and clients armed with AI are now exploiting it faster than firms can respond.
© Copyright 2026 ALM Global, LLC trading as Centellic.
Advertise with Us Customer Support Terms of Service Privacy Policy
